STUDENT JAMA, has functioned as a refreshing space for an exchange of the ideas of future physicians. In these pages, students have considered spiritual assessment of patients, the global HIV/AIDS pandemic, and their own experience of medical education. They have reflected on the nature of healing and spoken to the issues at the core of caring for patients.

The Editorial announcing the end of STUDENT JAMA addressed the emerging emphasis on evidence over opinion. To remove STUDENT JAMA from the journal in the interest of “incorporat[ing] high-quality articles” misses the function of the section. Students, of course, will rarely publish research of the type and quality demanded by the pages of JAMA, but what students bring is as important. Students write and speak of the ideals of medicine, of their hope for the best patient care, of their struggles to forge new identities as healers. And in the process of exchanging ideas over the pages of JAMA, we believe that medical students offer our senior colleagues a chance to reflect on their own work as a physician.

For a generation, JAMA saw these attributes as central to its mission. Indeed, they align well with 3 of JAMA’s 9 objectives: to foster responsible and balanced debate on issues that affect medicine and health care, to anticipate important issues and trends in medicine and health care, and to inform readers about nonclinical aspects of medicine and public health, including the political, philosophic, ethical, legal, environmental, economic, historical, and cultural.  

Medical students will benefit from JAMA’s development of an elective in medical journalism and enriched manuscript review for student research submissions. These enhancements are appropriate and important, but they in no way speak to the void left by removing a student section from JAMA. We regret this decision.

Brian Palmer, MD, MS, MPH
pres@www.amsa.org
National President
American Medical Student Association
Reston, Va
Yvette Martin
Chair, Organization of Student Representatives
Association of American Medical Colleges
Washington, DC

We believe that, with a little extra assistance, medical students can and will be able to publish all types of articles in JAMA. Since publication of our editorial, we have accepted 2 research papers in which medical students are the first author. In addition, we have had a number of inquiries and submissions from medical students, as well as inquiries about the medical student elective in medical journalism.

We ask Palmer and Martin to have patience and let the evidence prove which is the more beneficial method for medical students to have a forum for their work.

Catherine D. DeAngelis, MD, MPH
Editor-in-Chief
Phil B. Fontanarosa, MD
Executive Deputy Editor
JAMA

RESEARCH LETTER

Age-Related Testosterone Depletion and the Development of Alzheimer Disease

To the Editor: Normal male aging is associated with declines in serum levels of the sex steroid hormone testosterone, which contributes to a range of disorders including osteoporosis and sarcopenia.  

Unknown is how this relationship applies to age-related disorders in the brain, an androgen-responsive tissue. We hypothesize that testosterone levels in the brain are depleted as a normal consequence of male aging and that low brain levels of testosterone increase the risk of developing Alzheimer disease (AD). Recent data suggest a correspondence between reduced serum levels of testosterone and the clinical diagnosis of AD. However, it is unclear whether testosterone depletion contributes to or results from the disease process. To investigate this issue, testosterone and estradiol levels were analyzed in postmortem brain tissue of elderly men and compared with their neuropathological diagnoses.

Methods. Brain tissue from men who had provided informed consent was collected at autopsy by repositories associated with Alzheimer’s Disease Research Centers at University of Southern California; University of California, Irvine; University of California, San Diego; and Duke University. Tissue was collected between 1997 and 2003, with postmortem delay less than 8 hours (mean delay = 4.6 hours). Subjects with conditions associated with altered testosterone levels (eg, end-stage renal disease, liver disease, alcoholism, and diabetes) were excluded from the study. Included subjects satisfied 1 of the following neuropathological diagnoses: (1) neurologically normal (controls) (Braak stage 0-1 without evidence of other degenerative changes, and lacking a clinical history of cognitive impairment; n = 17), (2) AD (Braak stage 3-6 with neuropathological diagnosis of AD in the absence of other neuropathology; n = 19), and (3) mild neuropathological changes (Braak stage 2-3 in the absence of discrete neuropathology; n = 9). No subjects were neuropathologically diagnosed with Braak stage...
Estradiol levels in age-matched controls, subjects with MNC, and subjects with Alzheimer disease (AD). Right, Testosterone and estradiol levels were measured by radioimmunoassay of homogenates of brain samples from the midfrontal gyrus following organic extraction and celite column partition chromatography.4 Hormone levels expressed as hormone weight per wet tissue weight were statistically compared using analysis of covariance with age as the covariate. This study was performed with institutional review board approval from the University of Southern California.

Results. We observed that brain levels of testosterone but not estradiol (Figure 1) were inversely correlated with age in men aged 50 to 97 years who were diagnosed as neuropathologically normal. To investigate whether this depletion of brain testosterone may be a risk factor for the development of AD, we compared hormone levels among elderly men who exhibited no neuropathology, mild neuropathological changes, or moderate to severe AD. Men in the 3 groups were of similar age, ranging from 60 to 80 years with mean (SD) ages of 70.9 (5.3), 72.9 (5.7), and 72.0 (6.5) years, respectively, using analysis of variance (F = 0.002, P = .97). We found that brain levels of testosterone but not estradiol (Figure 2) are significantly lower in AD subjects compared with the control subjects. We found that brain levels of testosterone are also significantly reduced in men with mild neuropathology consistent with early stage AD (Figure 2).

Comment. Brain levels of testosterone significantly decrease with age in men who lack any evidence of neuropathology, suggesting that neural androgen depletion is a normal consequence of aging. In comparison with the control subjects, men with AD exhibit significantly lower testosterone levels in the brain. In contrast, the data suggest that estrogen levels in the male brain are affected by neither advancing age nor AD diagnosis. Notably, testosterone depletion likely precedes and thus may contribute to rather than result from the development of AD, since low brain testosterone is observed in men with early indications of AD neuropathology. Although it remains possible that low testosterone may reflect an unmeasured correlate of AD rather than be a contributing factor, we controlled for established causes of low testosterone by our exclusion criteria and statistical adjustment. How testosterone depletion may contribute to AD development is unknown. However, we have recently reported that androgen depletion in male rodents increases brain levels of β-amyloid,3 the protein implicated as a causal factor in AD pathogenesis, and decreases neuronal survival upon exposure to toxic insult.6 Collectively, these findings suggest that normal, age-related testosterone depletion in the male brain may impair beneficial neural actions of androgens and thereby act as a risk factor for the development of AD.

Emily R. Rosario, MS
Neuroscience Graduate Program
Lilly Chang, MD
Frank Z. Stanczyk, PhD
Department of Obstetrics and Gynecology
Keck School of Medicine
Christian J. Pike, PhD
cjpike@usc.edu
Andrus Gerontology Center
University of Southern California
Los Angeles

Funding/Support: This study was supported by a grant from the National Institute on Aging (AG14751 to Dr Pike). Tissue was obtained from the Alzheimer’s Disease Research Centers at the University of Southern California AG05142, University of California Irvine AG16573, University of California San Diego AG05131, and Duke University AG05128.